NOVOTECH
28.8.2024 14:06:26 CEST | Business Wire | Press release
Novotech, a global full-service clinical Contract Research Organization (CRO), proudly announces its continued recognition as a Workplace Gender Equality Agency (WGEA) Employer of Choice for Gender Equality (EOCGE) in 2024. This marks another milestone in Novotech's ongoing commitment to fostering an inclusive and equitable workplace.
The EOCGE certification is a prestigious accolade in Australia's business landscape, acknowledging organizations that demonstrate exceptional dedication to achieving gender equality. This voluntary program recognizes employers who go above and beyond in creating an environment where all employees, regardless of gender, can thrive and succeed.
Novotech is one of only 81 companies that have held this award continually since 2023. Employers aiming to achieve the certification must demonstrate what they are doing to close their own gender pay gap, and through employee consultation, create policies and strategies to prevent sex-based harassment and discrimination, while setting targets for improving gender equality outcomes. They must account for their progress every two years.
Dr. John Moller, CEO of Novotech stated: "Receiving this re-certification in 2024 is a testament to our unwavering dedication to diversity and inclusion. It reflects the collective effort of our entire organization to champion these values. As we expand globally, we're committed to extending these best practices across all our operations, aiming to inspire positive change throughout our industry."
Angela Edwardson, Chief People Officer of Novotech added: "Our journey towards gender equality is an ongoing process deeply embedded in our corporate culture. The initiatives we've implemented as a WGEA Employer of Choice are not just policies on paper; they shape our daily operations, influence our strategic decisions, and contribute to a workplace environment that nurtures talent irrespective of gender."
Mary Wooldridge, CEO of WGEA: “In taking action to improve gender equality, EOCGE employers unlock enormous benefits for their business. Employees are more likely to join and to stay in organizations that prioritize a culture of equality and inclusion. Research also shows that businesses with greater gender balance in leadership roles are more profitable and productive.”
Novotech stands out among the select group of Australian employers in maintaining this prestigious citation, showcasing its sustained commitment to gender equality. As the company continues to grow and evolve, its dedication to creating an inclusive, diverse, and equitable workplace remains at the forefront of its organizational values, positively impacting the lives and careers of our employees.
The WGEA Employer of Choice for Gender Equality citation reaffirms Novotech's position as a leader in workplace equality. It not only sets a benchmark for the biotech and CRO sectors in Australia and internationally but also inspires others to follow suit, making us all proud to be a leader of this positive change in our industry.
About Novotech Novotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
Background: The WGEA EOCGE citation
Criteria for the citation cover leadership, learning and development, gender pay gaps, flexible working and other initiatives to support family responsibilities.
The criteria also ask employers about employee consultation, policies and strategies to prevent sex-based harassment and discrimination, and targets for improving gender equality outcomes.
Employers must demonstrate what they are doing to close their own gender pay gap by conducting an annual analysis of what’s driving their gender pay gap and following up on this by setting targets and identifying actions to reduce it. They must account for their progress every 2 years.
The Agency’s certification process also requires employee confirmation that there’s a zero-tolerance approach to gender-based harassment and sexual harassment, and that managers genuinely create environments within their teams that support equality for all employees.
The criteria are regularly strengthened to reflect best practice.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240826774489/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
